Literature DB >> 36205803

Gastrointestinal colonization by OXA-48-producing Enterobacterales: risk factors for persistent carriage.

O Lima1,2, A Sousa3,4, A Filgueira5, M Carmen González-Novoa6, Celina Domínguez-López4, M Ávila-Nuñez3, M Represa3, P Rubiñán3, L Martínez-Lamas7, Sonia Pérez-Castro6, M Rubianes3, M T Pérez-Rodríguez3,4.   

Abstract

Carbapenem-resistant Enterobacterales (CRE) infections are a major health problem. Intestinal colonization is a key factor in developing infection. However, factors associated with persistent colonization by CRE are unknown. The aim of the study was to identify factors associated with persistent CRE gut colonization. This is a retrospective, single-centre, observational study of adult patients with CRE gut colonization between January 2015 and January 2020. Epidemiologic characteristics, comorbidities, infectious events, duration of hospitalization and antimicrobial treatment received in the follow-up period were collected. Colonization was defined as isolation in at least 2 rectal swab culture samples of CRE. Decolonization was defined as 3 negative rectal swab cultures or 2 negative cultures and a negative molecular test. A cohort of 86 patients with CRE gut colonization was selected: 44 patients with spontaneous decolonization (DC) and 42 patients with persistent colonization (PC). The mean follow-up period was 24 months (IQR 14-33) in the DC group vs. 25 months (IQR 16-36) in the PC group (p = 0.478). Patient characteristics were similar between both groups. Colonization by other MDR microorganisms was high (44 patients, 51%) and slightly more common in the PC group (PC 60% vs. DC 43%, p = 0.139). The use of ceftazidime-avibactam was more common among the PC group (PC 33% vs. DC 14%, p = 0.041). We observed a higher percentage of antimicrobial therapy in the previous 30 days (PC 68% vs. DC 57%, p = 0.371) and 90 days (PC 81% vs. DC 82%, p = 0.353) in the PC group. Multivariable analysis showed that patients that have received ceftazidime-avibactam therapy (OR 4.9 95% CI [1.45-16.39], p = 0.010), and those colonized by other MDR microorganisms (OR 2.5, 95% CI [0.96-6.25], p = 0.060) presented a higher risk of PC. Ceftazidime-avibactam use and colonization by other MDR microorganisms might be associated with CRE persistent gut colonization.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Carbapenem-resistant; Enterobacterales; Gut carriage; OXA-48-type

Year:  2022        PMID: 36205803     DOI: 10.1007/s10096-022-04504-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   5.103


  15 in total

1.  Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.

Authors:  Adrian Sousa; María Teresa Pérez-Rodríguez; Adriana Soto; Lorena Rodríguez; Antonio Pérez-Landeiro; Lucia Martínez-Lamas; Andrés Nodar; Manuel Crespo
Journal:  J Antimicrob Chemother       Date:  2018-11-01       Impact factor: 5.790

2.  Progress in development of the index of ADL.

Authors:  S Katz; T D Downs; H R Cash; R C Grotz
Journal:  Gerontologist       Date:  1970

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study.

Authors:  Matteo Bassetti; Novella Carannante; Carlo Pallotto; Elda Righi; Giovanni Di Caprio; Mariano Bernardo; Giuseppe Sodano; Enza Mallardo; Daniela Francisci; Assunta Sartor; Elena Graziano; Carlo Tascini
Journal:  J Glob Antimicrob Resist       Date:  2018-11-20       Impact factor: 4.035

5.  Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections.

Authors:  N Deborah Friedman; Keith S Kaye; Jason E Stout; Sarah A McGarry; Sharon L Trivette; Jane P Briggs; Wanda Lamm; Connie Clark; Jennifer MacFarquhar; Aaron L Walton; L Barth Reller; Daniel J Sexton
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

Review 6.  Effect of new antimicrobial agents on the ecological balance of human microflora.

Authors:  Mamun-Ur Rashid; Andrej Weintraub; Carl Erik Nord
Journal:  Anaerobe       Date:  2011-12-02       Impact factor: 3.331

7.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).

Authors:  Mical Paul; Elena Carrara; Pilar Retamar; Thomas Tängdén; Roni Bitterman; Robert A Bonomo; Jan de Waele; George L Daikos; Murat Akova; Stephan Harbarth; Celine Pulcini; José Garnacho-Montero; Katja Seme; Mario Tumbarello; Paul Christoffer Lindemann; Sumanth Gandra; Yunsong Yu; Matteo Bassetti; Johan W Mouton; Evelina Tacconelli; Jesús Rodríguez-Baño
Journal:  Clin Microbiol Infect       Date:  2021-12-16       Impact factor: 8.067

8.  Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing Klebsiella pneumoniae.

Authors:  Isabel Machuca; Belén Gutiérrez-Gutiérrez; Salvador Pérez Cortés; Irene Gracia-Ahufinger; Josefina Serrano; María Dolores Madrigal; José Barcala; Fernando Rodríguez-López; Jesús Rodríguez-Baño; Julián Torre-Cisneros
Journal:  J Antimicrob Chemother       Date:  2016-07-26       Impact factor: 5.790

9.  Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae.

Authors:  Laurent Poirel; Claire Héritier; Venus Tolün; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Authors:  Evelina Tacconelli; Elena Carrara; Alessia Savoldi; Stephan Harbarth; Marc Mendelson; Dominique L Monnet; Céline Pulcini; Gunnar Kahlmeter; Jan Kluytmans; Yehuda Carmeli; Marc Ouellette; Kevin Outterson; Jean Patel; Marco Cavaleri; Edward M Cox; Chris R Houchens; M Lindsay Grayson; Paul Hansen; Nalini Singh; Ursula Theuretzbacher; Nicola Magrini
Journal:  Lancet Infect Dis       Date:  2017-12-21       Impact factor: 71.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.